Predict your next investment

OncoResponse company logo
Corporation
HEALTHCARE | Biotechnology
oncoresponseinc.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series C | Alive

Total Raised

$103.1M

Last Raised

$40.6M | 6 mos ago

About OncoResponse

OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to increase the success rate of these therapies across multiple cancer types.

OncoResponse Headquarter Location

1124 Columbia St Suite 300

Seattle, Washington, 98104,

United States

206-805-1600

Latest OncoResponse News

OncoResponse Appoints Sean McCarthy to Board of Directors

Jul 7, 2021

07/07/2021 | 07:02am EDT Message : *Required fields SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to immunosuppressive myeloid targets for cancer immunotherapy, today announced the appointment of Sean A. McCarthy, D. Phil., as an Independent Director to its Board of Directors. Dr. McCarthy brings over 20 years of experience in the biotechnology industry having served in roles in R&D, business development, finance and general management and currently serves as President, Chief Executive Officer and Chairman of CytomX. “Sean is a highly accomplished executive in our industry and has a wonderful breadth of perspective and experience,” said Clifford Stocks, Chief Executive Officer of OncoResponse. “As a skilled scientific and business leader, Sean deftly guided CytomX from development-stage to publicly-held company and is directly familiar with the growth opportunity ahead for OncoResponse. His advice and counsel will be valuable as we harness our drug discovery and development efforts to deliver impactful cancer therapies.” Dr. McCarthy joined CytomX in 2010 as Chief Business Officer and has served as Chief Executive Officer since 2011. Previously, Dr. McCarthy spent four years as a Transactional Partner at Pappas Ventures. Prior to Pappas, Sean drove a strategic reorganization of SGX Pharmaceuticals from a platform model to product-focused oncology company and served in multiple roles at Millennium Pharmaceuticals. Dr. McCarthy is an author on multiple peer-reviewed scientific publications and issued patents and remains a member of the Board of Directors and Executive Committee of the California Life Sciences Association. Dr. McCarthy received his Bachelor of Science degree in biochemistry and pharmacology at King’s College, University of London. He also received an MBA from the Rady School of Management at UCSD and a D. Phil. in cancer biology from St. John’s College, University of Oxford. “I am delighted to join the Board of OncoResponse and help advance their innovative approach to leveraging the human immune system to fight cancer,” said Dr. McCarthy. “The Company’s growing pipeline of antibody therapeutics which target unique aspects of the tumor microenvironment are moving OncoResponse to the forefront. I look forward to working with fellow Board members and Company leadership to further strengthen OncoResponse and transform the treatment of cancer.” ABOUT ONCORESPONSE OncoResponse, Inc., an immuno-oncology focused biotech company, in a broad strategic alliance with MD Anderson Cancer Center, uses a proprietary B-cell technology platform to mine the immune system of cancer patients who have responded to cancer immunotherapy to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies to treat cancer. OncoResponse has several antibodies directed at modulating immunosuppression of the tumor microenvironment in pre-clinical development and a CD163 targeting antibody entering clinical studies summer 2021. OncoResponse, Inc. is a privately held company backed by investment from MD Anderson Cancer Center, Rivervest Venture Partners, Redmile Group, Magnetar Group, Yonjin Venture, Bering Capital, ARCH Venture Partners, Helsinn Investment Fund, Canaan Partners, GreatPoint Ventures, Takeda Ventures, Buchang Pharma, Alexandria Real Estate Equities and William Marsh Rice University. For more information please visit:  www.oncoresponseinc.com INVESTOR CONTACT:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OncoResponse

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OncoResponse is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,589 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,762 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

OncoResponse Patents

OncoResponse has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Experimental cancer drugs
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/22/2020

6/15/2021

Monoclonal antibodies, Immune system, Clusters of differentiation, Immunology, Experimental cancer drugs

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/22/2020

00/00/0000

Grant Date

6/15/2021

00/00/0000

Title

Subscribe to see more

Related Topics

Monoclonal antibodies, Immune system, Clusters of differentiation, Immunology, Experimental cancer drugs

Subscribe to see more

Status

Grant

Subscribe to see more

OncoResponse Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OncoResponse Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.